Prostate Cancer Screening Using a Combination of Risk-Prediction, MRI, and Targeted Prostate Biopsies
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial
Lancet Oncol 2021 Sep 01;22(9)1240-1249, T Nordström, A Discacciati, M Bergman, M Clements, M Aly, M Annerstedt, A Glaessgen, S Carlsson, F Jäderling, M Eklund, H GrönbergFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.